Skandinaviska Enskilda Banken AB publ lowered its stake in Cooper Companies Inc (NYSE:COO) by 5.3% during the 1st quarter, HoldingsChannel reports. The firm owned 9,080 shares of the medical device company’s stock after selling 510 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Cooper Companies were worth $2,503,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of the business. Optimal Asset Management Inc. raised its stake in Cooper Companies by 116.0% during the 1st quarter. Optimal Asset Management Inc. now owns 8,504 shares of the medical device company’s stock valued at $2,344,000 after buying an additional 4,567 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Cooper Companies by 22.1% in the first quarter. The Manufacturers Life Insurance Company now owns 328,105 shares of the medical device company’s stock worth $90,449,000 after acquiring an additional 59,335 shares during the period. Maverick Capital Ltd. increased its position in Cooper Companies by 11.4% during the first quarter. Maverick Capital Ltd. now owns 7,089 shares of the medical device company’s stock valued at $1,954,000 after acquiring an additional 728 shares during the last quarter. APG Asset Management N.V. increased its position in Cooper Companies by 44.9% during the first quarter. APG Asset Management N.V. now owns 65,565 shares of the medical device company’s stock valued at $18,074,000 after acquiring an additional 20,301 shares during the last quarter. Finally, Waddell & Reed Financial Inc. lifted its holdings in Cooper Companies by 39,344.6% in the first quarter. Waddell & Reed Financial Inc. now owns 259,151 shares of the medical device company’s stock valued at $71,440,000 after acquiring an additional 258,494 shares during the period. 88.09% of the stock is owned by institutional investors and hedge funds.

In other news, SVP Agostino Ricupati bought 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were bought at an average cost of $281.47 per share, for a total transaction of $281,470.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Holly R. Sheffield purchased 880 shares of the company’s stock in a transaction that occurred on Friday, June 12th. The shares were purchased at an average cost of $283.18 per share, with a total value of $249,198.40. Following the completion of the purchase, the executive vice president now owns 930 shares of the company’s stock, valued at approximately $263,357.40. The disclosure for this purchase can be found here. 1.40% of the stock is owned by insiders.

NYSE:COO opened at $270.93 on Tuesday. The stock has a market cap of $14.56 billion, a PE ratio of 39.44, a P/E/G ratio of 2.81 and a beta of 0.92. The company has a quick ratio of 0.58, a current ratio of 1.14 and a debt-to-equity ratio of 0.37. The business’s 50-day simple moving average is $299.29 and its two-hundred day simple moving average is $312.65. Cooper Companies Inc has a 52 week low of $236.68 and a 52 week high of $365.68.

Cooper Companies (NYSE:COO) last announced its quarterly earnings data on Thursday, June 4th. The medical device company reported $1.51 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.29 by ($0.78). Cooper Companies had a net margin of 13.50% and a return on equity of 14.67%. The company had revenue of $524.90 million for the quarter, compared to analysts’ expectations of $604.78 million. During the same period last year, the business earned $2.94 earnings per share. The company’s quarterly revenue was down 19.7% compared to the same quarter last year. Sell-side analysts anticipate that Cooper Companies Inc will post 8.84 earnings per share for the current fiscal year.

Several equities research analysts have recently commented on the stock. Piper Sandler upped their price target on shares of Cooper Companies from $344.00 to $351.00 in a research report on Friday, March 6th. Stephens boosted their price objective on shares of Cooper Companies from $300.00 to $325.00 and gave the company an “overweight” rating in a research report on Tuesday, May 26th. Stifel Nicolaus raised their target price on Cooper Companies from $320.00 to $350.00 and gave the stock a “buy” rating in a report on Friday, March 6th. Jefferies Financial Group lowered their target price on Cooper Companies from $360.00 to $340.00 and set a “buy” rating on the stock in a research report on Wednesday, April 8th. Finally, Citigroup reduced their price target on Cooper Companies from $360.00 to $318.00 and set a “neutral” rating for the company in a research report on Friday, March 27th. Four research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Cooper Companies currently has a consensus rating of “Buy” and a consensus price target of $335.75.

Cooper Companies Company Profile

The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.

Featured Story: Learning About the VIX – Volatility Index

Want to see what other hedge funds are holding COO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cooper Companies Inc (NYSE:COO).

Institutional Ownership by Quarter for Cooper Companies (NYSE:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.